Sysmex (6869.T) Saham Harga
Sysmex Harga
Pendapatan tumbuh 8,8% per tahun selama 19 tahun terakhir menjadi 500,01 miliar JPY. Laba per saham tumbuh 7,5% per tahun selama 19 tahun terakhir. margin bersih Sysmex saat ini 7,1%, turun dari 12,1% beberapa tahun lalu. Sysmex saat ini menawarkan imbal hasil dividen sekitar 2,97%. Rasio pembayaran sekitar 39% dari laba. Dividen tumbuh 15,9% per tahun selama 19 tahun terakhir. Target harga median analis adalah 2.320,50 JPY, di atas harga saat ini sebesar 25,2%. Dari 21 analis, 16 merekomendasikan beli — konsensus keseluruhan Beli.
Harga saham Sysmex
Akses data ini lewat Eulerpool API
100.000 permintaan/bulan gratis · tanpa kartu
Model bisnis dan analisis saham Sysmex
Pertanyaan yang sering diajukan tentang saham Sysmex
Sysmex Corp is a leading healthcare company specializing in diagnostic testing equipment and technologies. The business model of Sysmex Corp revolves around the design, development, and manufacture of innovative testing systems for clinical laboratories and healthcare institutions. With a strong focus on hematological analysis and hemostasis, Sysmex Corp provides highly accurate and reliable diagnostic solutions to support disease detection, monitoring, and treatment. By leveraging advanced technologies and automation, the company enables efficient and precise diagnostic processes, ultimately contributing to better patient outcomes. Sysmex Corp's business model centers on delivering cutting-edge diagnostic solutions that empower healthcare professionals with the tools they need for accurate and timely diagnoses.
Sysmex Corp is primarily active in the healthcare and medical technology industries.
The main competitors of Sysmex Corp in the market include Abbott Laboratories, Siemens Healthineers, and Becton, Dickinson and Company (BD).
Sysmex Corp is a renowned healthcare company specializing in diagnostic solutions for medical organizations. Founded in 1968, Sysmex Corp has since achieved global recognition for its advanced technologies and commitment to improving medical diagnoses and treatments. The company offers a wide range of innovative products, including automated clinical laboratory systems, reagents, and software. Sysmex Corp has established itself as a leader in the field of blood and urinalysis testing, leveraging cutting-edge research and partnerships to enhance patient care. With a rich history spanning several decades, Sysmex Corp continues to revolutionize the healthcare industry with its strategic advancements and dedication to improving medical outcomes worldwide.
Sysmex Corp has achieved several significant milestones throughout its history. Some of these achievements include the development of the world's first automated blood coagulation analyzer, the introduction of the first fully automated urine sediment analyzer, and the establishment of international subsidiaries to expand its global presence. Sysmex Corp has also made advancements in the field of hematology, with the production of automated blood cell analyzers that provide accurate and efficient results. Additionally, the company has received recognition for its contributions to healthcare, such as the Japan Medical Device Excellence Award. Overall, Sysmex Corp's commitment to innovation and quality has led to various notable milestones in the medical technology industry.
Sysmex Corp is primarily present in various countries and regions across the globe. Some of the key markets where Sysmex Corp has a significant presence include Japan, the company's home country, where it is headquartered. Sysmex Corp also has a strong foothold in the Asia-Pacific region, particularly in China, South Korea, and India. Furthermore, Sysmex Corp has expanded its operations and established a notable presence in North America, primarily in the United States. Additionally, Sysmex Corp has a growing presence in Europe, with key markets such as Germany, France, and the United Kingdom.
Sysmex Corp represents values of integrity, innovation, and collaboration. With a strong corporate philosophy that revolves around contributing to the advancement of healthcare, Sysmex Corp is committed to providing reliable and efficient diagnostic solutions. The company prioritizes sustainable growth, social responsibility, and customer satisfaction. Through their cutting-edge technologies and solutions in the field of laboratory testing, Sysmex Corp aims to improve patient outcomes and enhance overall healthcare globally. With their dedication to excellence and continuous improvement, Sysmex Corp has established itself as a trusted leader in the healthcare industry.
Analis saat ini menetapkan target harga rata-rata 2.391,26 JPY untuk saham Sysmex (median: 2.320,50 JPY), yaitu +29,0 % terhadap harga terbaru. Konsensus didasarkan pada 21 peringkat analis.
21 analis saat ini menilai saham Sysmex: 16 merekomendasikan beli, 5 tahan, dan 0 jual.
Dengan kurs saat ini, saham Sysmex diperdagangkan pada 10,46 EUR (1.853,50 JPY).
Saham Sysmex (6869.T) tercatat di 4 bursa, termasuk: Tokio (JPX) (6869.T), Frankfurt (0YX.F), München (0YX.MU).
Sysmex Corp is a Japanese manufacturer of medical diagnostic devices and systems. The company is a global leader in the development and production of hematology and urine analysis devices, coagulation analysis devices, immunoassay systems, cell imaging devices, and laboratory automation solutions. The company is divided into three business segments: Diagnostic Business, Life Science Business, and IT Business. The Diagnostic Business focuses on the development and production of hematology and urine analysis devices and coagulation analysis devices, which are used in various medical fields such as hematology, oncology, pediatrics, and intensive care medicine. The Life Science Business includes immunoassay systems, cell imaging devices, and laboratory automation solutions, which are used in research and development, diagnostics, and drug development. The IT Business provides IT-based solutions for the medical fields served by the other business segments, aiming to efficiently collect and process data. Sysmex Corp is known for its research and development efforts, as well as its manufacturing capabilities, and it has established itself as an important player in the global healthcare industry. The company has a strong presence in international markets, with branches in over 190 countries. Sysmex Corp has partnerships with leading companies in the medical and pharmaceutical industries, allowing it to further strengthen and expand its position in the market. The company has a customer-oriented approach and strives to meet the needs of its clients. Overall, Sysmex Corp has revolutionized and modernized various medical fields with its unique products and services, making a significant contribution to the global healthcare industry.
Pendapatan dari Sysmex adalah 500,01 miliar JPY. Angka ini didasarkan pada data keuangan terkini dan mencerminkan kinerja bisnis perusahaan.
Laba dari Sysmex adalah 35,46 miliar JPY. Laba bersih mencerminkan profitabilitas perusahaan setelah mengurangi semua biaya.
Rasio harga-terhadap-pendapatan (PER) Sysmex saat ini adalah 32,06. PER membandingkan harga saham saat ini dengan laba per saham dan membantu investor menilai valuasi saham Sysmex.
Rasio harga-terhadap-penjualan (PSR) Sysmex saat ini adalah 2,27. PSR membandingkan kapitalisasi pasar dengan pendapatan tahunan dan berfungsi sebagai metrik valuasi untuk saham Sysmex.
Skor Kualitas AlleAktien untuk Sysmex adalah 6/10.
ISIN dari Sysmex adalah JP3351100007. ISIN (International Securities Identification Number) adalah identifikasi unik global untuk sekuritas.
WKN dari Sysmex adalah 897966. WKN (Wertpapierkennnummer) adalah kode identifikasi sekuritas Jerman enam digit.
Ticker dari Sysmex adalah 6869.T. Simbol ticker digunakan untuk memperdagangkan saham Sysmex di bursa saham.
Saham Sysmex
Kelompok Peer Sysmex
Sysmex Ticker
Sysmex FIGI
Semua metrik fundamental dan analisis mendalam Sysmex
Analisis saham kami untuk saham Sysmex mencakup kalkulasi keuangan penting seperti pendapatan, keuntungan, P/E ratio (P/E), P/S ratio (P/S), EBIT, serta informasi tentang dividen. Selain itu, kami juga mengamati aspek-aspek seperti saham, kapitalisasi pasar, utang, ekuitas, dan kewajiban dari Sysmex. Jika Anda mencari informasi lebih rinci tentang topik-topik ini, kami menawarkan analisis terperinci di subhalaman kami.